These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19553802)

  • 21. Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.
    Noël A; Jost M; Lambert V; Lecomte J; Rakic JM
    Trends Mol Med; 2007 Aug; 13(8):345-52. PubMed ID: 17644433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silence is golden: can RNA interference therapeutics deliver?
    Beal J
    Drug Discov Today; 2005 Feb; 10(3):169-72. PubMed ID: 15708529
    [No Abstract]   [Full Text] [Related]  

  • 24. Neovascular age-related macular degeneration: potential therapies.
    Chappelow AV; Kaiser PK
    Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting angiogenesis in retinoblastoma.
    Apte RS; Harbour JW
    Ophthalmic Res; 2007; 39(4):188-90. PubMed ID: 17556838
    [No Abstract]   [Full Text] [Related]  

  • 27. [New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy.].
    Pauleikhoff D; Kirchhof B; Bertram B; Holz FG; Bartz-Schmidt UB; Bornfeld N; Bresgen M; Heimann H; Helbig H; Hörauf H; Kampik A; Lemmen KD; Roider J
    Ophthalmologe; 2011 Jan; 108(1):85-90. PubMed ID: 21253745
    [No Abstract]   [Full Text] [Related]  

  • 28. Vascular endothelial growth factor biology: clinical implications for ocular treatments.
    Bhisitkul RB
    Br J Ophthalmol; 2006 Dec; 90(12):1542-7. PubMed ID: 17114590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
    Koldehoff M; Beelen DW; Elmaagacli AH
    J Leukoc Biol; 2008 Aug; 84(2):561-76. PubMed ID: 18458152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
    Mousa SA; Mousa SS
    BioDrugs; 2010 Jun; 24(3):183-94. PubMed ID: 20210371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Angiogenesis inhibitors for vision loss. Ranibizumab for macular degeneration].
    Mohr-Andrä M; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):437-40. PubMed ID: 17957687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
    Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
    J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.
    Hussain RM; Ciulla TA
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):235-246. PubMed ID: 28756707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interference RNA technology in the treatment of CNV.
    Tolentino M
    Ophthalmol Clin North Am; 2006 Sep; 19(3):393-9, vi-vii. PubMed ID: 16935214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new face of age-related macular degeneration.
    Giuliari GP; Ciardella AP
    Can J Ophthalmol; 2007 Aug; 42(4):629-30. PubMed ID: 17641716
    [No Abstract]   [Full Text] [Related]  

  • 38. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies.
    Wong TY
    Am J Ophthalmol; 2009 Sep; 148(3):327-9. PubMed ID: 19703607
    [No Abstract]   [Full Text] [Related]  

  • 39. [Anti VEGF therapy in different forms of wet ARMD].
    Panait OM
    Oftalmologia; 2011; 55(4):17-9. PubMed ID: 22642131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro.
    Stahl A; Paschek L; Martin G; Gross NJ; Feltgen N; Hansen LL; Agostini HT
    FEBS Lett; 2008 Sep; 582(20):3097-102. PubMed ID: 18703055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.